75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Unaudited Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Unaudited Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Unaudited Consolidated Statements of Operations and Comprehensive Loss 2 link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Unaudited Consolidated Statements of Series A Preferred Shares and Shareholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Unaudited Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Restricted Cash link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Net Loss Per Ordinary Share link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Geographic Data link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Net Loss Per Ordinary Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - The Company - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Share-Based Compensation - Summary of Options and RSUs Outstanding (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Collaboration Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Collaboration Agreements - Summary Of Allocation of The Total Transaction Price (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Net Loss Per Ordinary Share - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Net Loss Per Ordinary Share - Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Segment Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Segment Information - Schedule of Reconciliation to Consolidated Operating Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 999009 - Disclosure - Anchoring link:presentationLink link:calculationLink link:definitionLink Related Party Tax Expense, Due to Affiliates, Current Expenses incurred Consulting Agreement [Member] Consulting Agreement [Member] Consulting Agreement [Member] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Statement of Financial Position Location, Balance [Domain] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Plan Name [Axis] Plan Name Equity [Abstract] Entity Current Reporting Status Entity Current Reporting Status Operating Expenses [Abstract] Operating expenses: Temporary Equity, Par or Stated Value Per Share Series A preferred stock, par value Product and Service [Axis] Product and Service Document Fiscal Period Focus Document Fiscal Period Focus Other Noncurrent Liabilities [Member] Long-term Liabilities [Member] Rule 10 B 51 Arr Modified Flag Rule 10b5-1 arrangement modified. Rule 10b5-1 Arrangement Modified Entity Shell Company Entity Shell Company Temporary Equity, Shares Outstanding Temporary equity, Ending balance, shares Temporary equity, Beginning balance, shares Series A preferred stock, shares outstanding Series A preferred shares outstanding Christopher Francis [Member] Christopher Francis [Member] Christopher Francis. Cash and Cash Equivalent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Stock Issued During Period, Shares, Conversion of Units Conversion of Series A preferred shares to ordinary shares Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Statement [Table] Statement [Table] Increase (Decrease) in Prepaid Expense Prepaid expenses Statement [Line Items] Statement [Line Items] Entity Filer Category Entity Filer Category Liabilities and Equity Total liabilities, Series A preferred shares, and shareholders' equity Payables and Accruals [Abstract] Mark Corrigan [Member] Mark Corrigan [Member] Mark Corrigan. HD Program [Member] HD Programs [Member] HD programs. Shares Issued, Price Per Share Purchase price per share Options to employees and non-employee directors member. Options to Employees and Non-Employee Directors [Member] Options to Employees and Non-Employee Directors [Member] Options to Purchase Ordinary Shares [Member] Investment Income, Interest Interest income Assets, Noncurrent [Abstract] Long-term assets: Accrued expenses and other current liabilities. Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities Significant Accounting Policies [Text Block] Significant Accounting Policies INHBE program [Member] INHBE program. INHBE Program [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Options granted to employees GSK Collaboration Program [Member] GSK Collaboration Program [Member] GSK collaboration program. GSK Collaboration Programs [Member] Collaboration agreement commencement date. Collaboration Agreement Commencement Date Collaboration agreement commencement date Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Summary of Basic and Diluted Net Income (Loss) Attributable to Ordinary Shareholders Earnings Per Share, Basic, Total Earnings Per Share, Basic Net income (loss) per share attributable to ordinary shareholders - basic Net loss per share attributable to ordinary shareholders - basic Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Foreign currency translation gain (loss) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options to purchase ordinary shares Liabilities, Current Total current liabilities Increase (Decrease) in Accounts Receivable Accounts receivable Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Pre-funded warrant sold Class of warrant or right issued. Class Of Warrant Or Right Issued Trading Arrangement 5 [Member] Trading Arrangement 5 [Member] Trading Arrangement 5. Equity, Attributable to Parent [Abstract] Shareholders' equity Entity Small Business Entity Small Business Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Purchase price per share Sale of Stock, Price Per Share Share-Based Compensation Share-Based Payment Arrangement [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Contract with Customer, Liability Collaboration and license agreement, deferred revenue Contract with Customer, Liability, Total Amendment Flag Amendment Flag Product and Service [Domain] Product and Service Purchase price of pre-funded warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Segment Reporting Information, Operating Income (Loss) [Abstract] Liabilities and Equity [Abstract] Liabilities, Series A preferred shares, and shareholders' equity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Common Stock [Member] Ordinary Shares [Member] Shin Nippon Biomedical Laboratories Ltd. Shin Nippon Biomedical Laboratories Ltd [Member] Shin Nippon Biomedical Laboratories Ltd [Member] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Net of accumulated depreciation Non Rule 10b 51 Arr Modified Flag Non-Rule 10b5-1 Arrangement Modified. Non-Rule 10b5-1 Arrangement Modified Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Entity Address, Address Line One Entity Address, Address Line One Earnings Per Share [Abstract] Temporary Equity, Carrying Amount, Attributable to Parent Temporary equity, Ending balance Temporary equity, Beginning balance Series A preferred shares, no par value; nil and 3,901,348 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Scientific Advisor [Member] Scientific Advisor [Member] Scientific Advisor [Member] Chandra Vargeese [Member] Chandra Vargeese. Statement of Financial Position Location, Balance [Axis] Investment Type [Axis] Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Percentage of ownership interest at election of ordinary shares outstanding, minimum. Percentage of ownership interest at election of ordinary shares outstanding, minimum Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Restricted Cash and Cash Equivalent [Abstract] Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net decrease in cash, cash equivalents, and restricted cash Subsequent Event Type [Domain] Subsequent Event Type Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive shares excluded from computation of diluted earnings Issuance of pre funded warrants net. Issuance of Pre Funded Warrants Net Issuance of pre-funded warrants, net of offering costs Employee share purchase plan. Employee Share Purchase Plan [Member] ESPP [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Option exercises, shares Accrued Liabilities, Current Accrued expenses related to CROs and CMOs Accrued Liabilities, Current, Total Current Fiscal Year End Date Current Fiscal Year End Date Restricted Cash and Cash Equivalent, Noncurrent Restricted cash Restricted Cash and Cash Equivalents, Noncurrent, Total Heidi Wagner [Member] Heidi Wagner. Heidi Wagner [Member] Document Quarterly Report Document Quarterly Report Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Beginning Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number RSUs Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Number Ordinary shares repurchase Number Ordinary Shares Repurchase By Selling Pre funded Warrants Number ordinary shares repurchase by selling pre funded warrants. Common Stock, Capital Shares Reserved for Future Issuance Ordinary shares reserved for issuance Percentage of global costs and potential profits sharing ratio. Percentage Of Global Costs And Potential Profits Sharing Ratio Percentage of global costs and potential profits sharing ratio Category two programs. Category Two Programs [Member] Category Two Programs [Member] Accounts Receivable [Member] Stock Issued During Period, Value, Stock Options Exercised Option exercises Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Current Liabilities Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Other Comprehensive Income (Loss), Net of Tax [Abstract] Other comprehensive loss: Other comprehensive income (loss): Subsequent Event [Member] Subsequent Event [Member] Collaboration agreement committed cash. Collaboration Agreement Committed Cash Collaboration agreement, committed cash Other Assets, Noncurrent Other assets Antidilutive Securities [Axis] Antidilutive Securities Vesting percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Vesting percentage. Discovery Research Collaboration [Member] Discovery research collaboration. Discovery Research Collaboration [Member] Performance based restricted stock units. Performance Based Restricted Stock Units [Member] Performance-based RSUs [Member] Related Party Transaction [Axis] Related Party Transaction Accumulated Other Comprehensive Loss [Member] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Member] Collaboration And License Agreement [Member] Collaboration And License Agreement [Member] Collaboration and license agreement. Minimum [Member] Minimum [Member] Assets, Current [Abstract] Current assets: Collaboration and license agreement month and year. Collaboration And License Agreement Month And Year Collaboration and license agreement month and year Segment Reporting [Abstract] Liabilities, Current [Abstract] Current liabilities: Related Party Transactions [Abstract] Shares, Outstanding Ending balance, shares Beginning balance, shares Ordinary shares outstanding Accounts Receivable, after Allowance for Credit Loss, Current, Total Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Proceeds from the ESPP Proceeds from Stock Plans collaboration-budgeted research and preclinical expenses. Collaboration Budgeted Research And Preclinical Expenses Collaboration-budgeted research and preclinical expenses Fund receivable for research and preclinical activities. Fund Receivable For Research And Preclinical Activities Fund receivable for research and preclinical activities Common Stock, No Par Value Common stock, par value Share purchase price at equal to fair market value percentage Share Purchase Price At Equal To Fair Market Value Percentage Share purchase price at equal to fair market value percentage. Ordinary share purchase price at equal to fair market value percentage Concentration Risk Benchmark [Axis] Gross proceeds from sale of ordinary shares Gross Proceeds From Issuance Of Common Stock Gross proceeds from issuance of common stock. Liabilities, Noncurrent [Abstract] Long-term liabilities: Effect of foreign exchange rates on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Expenses incurred Expenses Related to Contract Research Services Expenses related to contract research services. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Up-front consideration received. Up Front Consideration Received Up-front consideration received Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Basic Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders - basic 2021 equity incentive plan. Two Thousand Twenty One Equity Incentive Plan [Member] 2021 Plan [Member] Trading Arrangement 4 [Member] Trading Arrangement 4. Trading Arrangement 4 [Member] Paul B. Bolno [Member] Paul B. Bolno. Trading Arrangement 3 [Member] Trading Arrangement 3. Trading Arrangement 3 [Member] Segment Reporting, Expense Information Used by CODM, Description Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] At-the-market equity program. At The Market Equity Program [Member] At-The-Market Equity Program [Member] Related Party Transactions Disclosure [Text Block] Related Party Transactions Equity, Attributable to Parent Ending balance Beginning balance Total shareholders' equity Basis of Accounting, Policy [Policy Text Block] Unaudited Interim Financial Data Statement of Stockholders' Equity [Abstract] Series A Preferred Stock [Member] Series A Preferred Shares [Member] Aggregate initiation payment Collaborative Arrangement Initiation Payment Collaborative arrangement initiation payment. Reduction to revenue recognition. Reduction To Revenue Recognition Reduction to revenue recognition Entity Address, Address Line Two Entity Address, Address Line Two Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Expenses and Other Current Liabilities Other Assets, Current Other current assets Accrued Liabilities and Other Liabilities Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Plan Name [Domain] Plan Name Increase (Decrease) in Other Operating Assets Other assets Increase (Decrease) in Other Operating Assets, Total AATD Program [Member] AATD program. AATD Program [Member] Class of Warrant or Right, Outstanding Pre-funded warrant outstanding Collaboration agreement upfront payment. Collaboration Agreement Upfront Payment Upfront payment under collaboration agreement Kyle Moran. Kyle Moran [Member] Kyle Moran [Member] Related and Nonrelated Parties [Axis] Related Party Pfizer Inc. [Member] Pfizer Inc. Pfizer Inc [Member] Entity Address, City or Town Entity Address, City or Town Number of Reportable Segments Number of Reportable Segments Security Exchange Name Security Exchange Name Counterparty Name [Axis] Counterparty Name Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Percentage of ownership interest in ordinary shares outstanding. Percentage of ownership interest in ordinary shares outstanding Minimum percentage of combined voting power of securities outstanding immediate effect of exercise Percentage of ownership interest in ordinary shares outstanding Statistical Measurement [Domain] Statistical Measurement Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant Exercise Price Per Share Pre-funded warrant exercise price per share Assets, Current Total current assets Share-based compensation expense Share-Based Payment Arrangement, Expense Summary Of Allocation of The Total Transaction Price Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Document Period End Date Document Period End Date Statement of Financial Position [Abstract] RSUs [Member] Restricted Stock Units (RSUs) [Member] RSUs to Employees [Member] Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Class of Stock [Axis] Series A Preferred Shares [Member] Liabilities Total liabilities Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders diluted Weighted Average Number of Shares Outstanding, Diluted Weighted-average ordinary shares used in computing net income (loss) per share attributable to ordinary shareholders - diluted Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders - diluted Collaboration and Share Purchase Agreements [Abstract] Collaboration And Share Purchase Agreements [Abstract] Securities Act File Number Entity File Number Gross proceeds related to exercise of underwriters' option Gross proceeds related to exercise of underwriters' option. Gross proceeds related to exercise of underwriters' option Cover [Abstract] Transaction Price Unsatisfied Transaction Price Unsatisfied To Performance Obligation Transaction price unsatisfied to performance obligation. Milestone payment Collaborative Arrangements Milestone Payment Collaborative arrangements milestone payment. Investments [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Increase in shares of common stock authorized for issuance Ordinary shares authorized for issuance Sale of Stock [Domain] Sale of Stock Geographic Data Disclosure [Text Block] Geographic Data Disclosure [Text Block] Geographic Data Segment Reporting Disclosure [Text Block] Segment Information Aik Na Tan [Member] Aik Na Tan. Aik Na Tan [Member] General and Administrative Expense General and administrative General and Administrative Expense, Total General and administrative expenses 2019 ESPP [Member] Two Thousand Nineteen Employee Share Purchase Plan [Member] Two thousand nineteen employee share purchase plan. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Minimum percentage of combined voting power of securities outstanding immediate effect of exercise Minimum percentage of combined voting power of securities outstanding immediate effect of exercise. Minimum percentage of combined voting power of securities outstanding immediate effect of exercise Contract with Customer, Liability, Current Current portion of deferred revenue Collaboration and license agreement, deferred revenue current Deferred revenue, net of current portion Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period DMD Program [Member] DMD Programs [Member] DMD programs. AATD Collaboration [Member] AATD Collaboration [Member] AATD Collaboration. Depreciation Depreciation of property and equipment Depreciation, Total Investment, Type [Extensible Enumeration] Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Operating Lease, Liability, Current Current portion of operating lease liability Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Transaction Price Allocated Revenue, Remaining Performance Obligation, Amount Document Transition Report Document Transition Report Two thousand fourteen equity incentive plan. Two Thousand Fourteen Equity Incentive Plan [Member] 2014 Plan [Member] Operating Expenses Total operating expenses Research and Development Expense Research and development Total research and development expenses Statement of Cash Flows [Abstract] Collaboration agreement in premium. Collaboration Agreement in Premium Stock Issued During Period, Value, New Issues Equity investment aggregate purchase price Issuance of ordinary shares pursuant to the "at-the-market" equity program, net Shareholders' Equity Equity [Text Block] Category 1 Programs and Category 2 Programs [Member] Category One Programs And Category Two Programs [Member] Category one programs and category two programs. Earnings Per Share [Text Block] Net Loss Per Ordinary Share Increase (decrease) in Operating lease liabilities. Increase Decrease In Operating Lease Liabilities Operating lease liabilities Net income (loss) Net loss Net loss Option to reach maximum targets for preclinical programs. Option To Reach Maximum Targets For Preclinical Programs Option to reach maximum targets for preclinical programs Assets [Abstract] Assets Document Fiscal Year Focus Document Fiscal Year Focus Concentration Risk Benchmark [Domain] Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Maximum targets for preclinical programs. Maximum Targets For Preclinical Programs Maximum targets for preclinical programs Deferred Revenue, Total Deferred Revenue Deferred revenue Time-based restricted stock units. Time Based Restricted Stock Units [Member] Time-based RSUs [Member] Adrian Rawcliffe [Member] Adrian Rawcliffe [Member] Adrian Rawcliffe [Member] Adjustment To Revenue Recognition Adjustment to revenue recognition. Adjustment to revenue recognition Proceeds from Stock Options Exercised Proceeds from the exercise of share options Share-Based Payment Arrangement [Abstract] Share-based compensation expense not yet recognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total Sale of Stock [Axis] Sale of Stock Payments related to contract research services. Payments Related to Contract Research Services Payments related to contract research services. Revenues, Total Revenues Revenue from agreement Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash used in investing activities GSK equity investment. G S K Equity Investment [Member] GSK Equity Investment [Member] Title of 12(b) Security Title of 12(b) Security Schedule of Segment Reporting Information, by Segment [Table] Stock Issued During Period, Value, Conversion of Units Conversion of Series A preferred shares to ordinary shares Trading Arrangement 1 [Member] Trading arrangement 1. GSK collaboration agreement. GSK Collaboration Agreement [Member] GSK Collaboration Agreement [Member] Maximum termination notice period. Maximum Termination Notice Period Collaboration agreement termination period Related and Nonrelated Parties [Domain] Related Party Income Tax Disclosure [Text Block] Income Taxes Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Temporary Equity, Shares Issued Series A preferred stock, shares issued Class of Warrant or Right [Line Items] C9-ALS/FTD Program [Member] C9-ALS/FTD Program Member C9-ALS/FTD program. Warrant or Right, Original issuance date, description Warrant or Right, Reason for Issuance, Description Total transaction price. Total Transaction Price Total transaction price Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Proceeds from issuance of ordinary shares pursuant to at-the-market equity program net. Proceeds From Issuance Of Ordinary Shares Pursuant To At-the-market Equity Program Net Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net of offering costs Proceeds from issuance of ordinary share pursuant to the at-the-market equity program, net of offering costs Income Tax Disclosure [Abstract] Acheivement of milestone included in current portion receivable Acheivement Of Milestone Included In Current Portion Receivable Acheivement of milestone included in current portion receivable Additional Paid-in Capital [Member] Additional Paid-In-Capital [Member] Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued expenses and other current liabilities Trading Symbol Trading Symbol Related Party Transaction [Table] Schedule Of Related Party Transactions By Related Party [Table] Subsequent Event Type [Axis] Subsequent Event Type Employee-related Liabilities, Current Accrued compensation Employee-related Liabilities, Current, Total Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows from financing activities Equity Components [Axis] Additional Paid-In-Capital [Member] Collaboration and Share Purchase Agreements [Member] Collaboration And Share Purchase Agreements [Member] Collaboration and share purchase agreements. Total other income, net Nonoperating Income (Expense) Percentage of ownership interest at election of ordinary shares outstanding maximum. Percentage of Ownership Interest at Election of Ordinary Shares Outstanding Maximum Percentage of ownership interest at election of ordinary shares outstanding maximum Equity Component [Domain] Equity Component Share-Based Payment Arrangement, Activity [Table Text Block] Summary of Options and RSUs Outstanding Equity investment agreement official closure date month and year. Equity Investment Agreement Official Closure Date Month And Year Equity investment agreement official closure month and year Class of Stock Disclosures [Abstract] Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture Share-based compensation Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of ordinary shares under ESPP, shares Number of shares issued Contractual life of options Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period September 2024 Offering. September 2024 Offering [Member] September 2024 Offering [Member] Maximum [Member] Maximum [Member] Statistical Measurement [Axis] Statistical Measurement Collaboration and license agreement, deferred revenue noncurrent Contract with Customer, Liability, Noncurrent Deferred revenue, net of current portion Prepaid Expense, Current Prepaid expenses Prepaid Expense, Current, Total Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Ordinary shares, no par value; 192,337,566 and 187,660,263 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively Collaboration and license agreement date. Collaboration And License Agreement Date Collaboration and License Agreement Date Service Period of October 1, 2022 Through December 31, 2024 [Member] Service Period Of October 1 2022 Through December 31 2024 [Member] Service period of October 1, 2022 through December 31, 2024. Related Party Transaction [Line Items] Related Party Transaction [Line Items] Entity Registrant Name Entity Registrant Name Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Other income (expense), net Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Income Tax Expense (Benefit) Income tax benefit (provision) Income Tax Expense (Benefit), Total Income tax (benefit) provision Income tax benefit (provision) Income tax benefit Proceeds from issuance of ordinary shares Net proceeds from sale of ordinary shares Proceeds from the issuance of ordinary shares, net of offering costs Developmental milestone related to HD Category 1 Program, which pertained to completion of new, non-clinical study of WVE-003 in non-human primates or NHPs member. Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member] Developmental Milestone related to HD Category One Program, Which Pertained to Completion of New, Non-Clinical Study of WVE-003 in Non-Human Primates or NHPs [Member] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement By Share-based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Revenue from termination of collaborative arrangement Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Shares granted to employees Assets Total assets Income Statement [Abstract] Takeda pharmaceutical company limited. Takeda Pharmaceutical Company Limited [Member] Takeda [Member] Sale of Stock, Number of Shares Issued in Transaction Additional shares of common stock Trading Arrangement 2 [Member] Trading arrangement 2. Shares issued under equity agreement Additional purchase of ordinary shares Issuance of ordinary shares pursuant to the "at-the-market" equity program, net, shares Earnings Per Share, Diluted, Total Earnings Per Share, Diluted Net income (loss) per share attributable to ordinary shareholders - diluted Net loss per share attributable to ordinary shareholders - diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Reconciliation to Consolidated Operating Expenses Preferred Stock, Conversion Basis Preferred shares, conversion basis City Area Code City Area Code Christian Henry [Member] Christian Henry. Christian Henry [Member] Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Total Other comprehensive loss Other comprehensive income (loss) Counterparty Name Counterparty Name [Domain] Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of ordinary shares under the ESPP Collaborative arrangement initiation payment received Collaborative Arrangement Initiation Payment Received Collaborative arrangement initiation payment received. Segment Reporting Information [Line Items] Pre Funded Warrants [Member] Pre Funded Warrants. Pre Funded Warrants (Member) Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Total Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Property and equipment, net of accumulated depreciation of $50,352 and $49,522 as of March 31, 2026 and December 31, 2025, respectively Restricted Assets Disclosure [Text Block] Restricted Cash Cash, cash equivalents, and restricted cash, end of period Cash, cash equivalents, and restricted cash, beginning of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Operating Income (Loss) Loss from operations Retained Earnings [Member] Accumulated Deficit [Member] Entity Address, Country Entity Address, Country Assets, Noncurrent Total long-term assets Percentage of combined voting power of securities outstanding at election of immediate effect of exercise minimum. Percentage of combined voting power of securities outstanding at election of immediate effect of exercise minimum Liabilities, Noncurrent Total long-term liabilities Category one programs. Category One Programs [Member] Category One Programs [Member] Percentage of combined voting power of securities outstanding at election of immediate effect of exercise maximum. Percentage of combined voting power of securities outstanding at election of immediate effect of exercise maximum Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Class of Stock [Line Items] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Other income, net: Nonoperating Income (Expense) [Abstract] Employee And Non Employee Stock Option [Member] Options [Member] Employee and non employee stock option. Anti-Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Ordinary Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Gregory Verdine [Member] Gregory Verdine. Gregory Verdine [Member] Entity Interactive Data Current Entity Interactive Data Current Increase (Decrease) in Contract with Customer, Liability Deferred revenue Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash flows from operating activities Stock issued during period shares restricted stock award vested. Stock Issued During Period Shares Restricted Stock Award Vested Vesting of RSUs, shares Amortization of right-of-use assets. Amortization Of Right Of Use Assets Amortization of right-of-use assets Reduction to revenue. Reduction To Revenue Reduction to revenue Reduction to revenue Entity Tax Identification Number Entity Tax Identification Number Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] The Company Collaborative Arrangement Transaction Statement Of Income Or Comprehensive Income Extensible Enumeration Not Disclosed Flag Collaborative arrangement transaction statement of income or comprehensive income extensible enumeration not disclosed flag. Local Phone Number Local Phone Number Related Party Transaction [Domain] Related Party Transaction Number Of Authorized Shares Not Disclosed Number of authorized shares not disclosed. Number of authorized shares not disclosed Accounting Policies [Abstract] Other Current Liabilities [Member] Current Liabilities [Member] Collaboration and license agreement research term. Collaboration And License Agreement Research Term Research term under collaboration and license agreement Revenue from Contract with Customer, Excluding Assessed Tax Revenue Collaboration revenue recognized Revenue from Contract with Customer, Excluding Assessed Tax, Total Revenue Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Geographic data. Geographic Data [Abstract] Class of Stock [Domain] Class of Stock Other research and development expenses, including PNPLA3, additional preclinical programs, PRISM. Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM Other Research and Development Expenses, Including PNPLA3, Additional Preclinical Programs, PRISM [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Ordinary shares available for future grant Stock, Class of Stock [Table] Entity Emerging Growth Company Entity Emerging Growth Company